The edition · Pulmonology
A mild exacerbation is not a mild finding, and taking coal out of rural homes moved symptoms
Three years of community COPD follow-up, a natural experiment in household fuel, blood signatures that predict who relapses after tuberculosis treatment, and what dupilumab does to individual mucus plugs.
The edition in brief
China's Clean Heating Policy, rolled out village by village across rural Beijing, gave a natural experiment in household air pollution: among 1,003 adults over 40 followed across four winters, exposure to the policy was associated with a 7.5 percentage point fall in the prevalence of any respiratory symptom, with no measurable change in exhaled nitric oxide. In 329 Brazilian adults with drug-susceptible pulmonary tuberculosis, blood transcriptomic signatures measured at baseline and at two months predicted later recurrence with areas under the curve from 0.71 to 0.91, and several measured at baseline predicted death with AUC of 0.80 or more — but prediction of microbiological treatment failure was poor throughout, and no signature met WHO benchmarks at the end of treatment. In 32 adults with moderate to severe asthma scanned before and after, dupilumab resolved 91% of individual mucus plugs against 58% in controls, produced far fewer new plugs, and lowered the radiodensity of those that persisted; the plugs that remained still tracked with ventilation defects. The practice-changer comes from 915 community-dwelling people with COPD: those whose only exacerbation in the previous year was mild, or a single moderate one, had 1.7 to 2.3 times the rate of subsequent exacerbations over three years, and more emphysema or air trapping on CT, than those with none — even though lung function declined at the same rate in all groups.
Taking coal out of rural homes reduced respiratory symptoms
Treat household fuel as a clinical exposure worth asking about and documenting — changing it moved symptoms at population scale.
Blood signatures that see tuberculosis recurrence coming, and cannot see failure
Nothing changes today — but if a blood signature reaches practice, it will be a two-month decision aid, not a test of cure.
Dupilumab clears mucus plugs, and what remains still matters
Mucus plugging looks like a modifiable trait rather than a fixed structural finding — but incomplete clearance is the usual outcome, and it still matters.
Ask the never-smoker with COPD what she cooks on
In a never-smoker with COPD, ask about cooking fuel, kitchen ventilation and hours of exposure — the cause is often still operating.
One mild exacerbation is a prediction, not a footnote
Ask about symptom episodes treated at home, and treat one mild or one moderate exacerbation as a reason to review therapy rather than as evidence of stability.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free